Evolutionary Genomics, Inc.

FNAM

US30051F1012

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:56:12 19/07/2023 am IST			5-day change	1st Jan Change
0.45 ^USD	-25.00%		-.--%	-.--%

2023	Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2023	Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt	CI

Evolutionary Genomics, Inc. announced that it has received $1.004004 million in funding

May 12, 2022

On May 12, 2022, Evolutionary Genomics, Inc. closed the transaction. The round included participation from 17 investors.

Latest news about Evolutionary Genomics, Inc.

Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt	09/23/09	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/22/21	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	08/22/08	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
Evolutionary Genomics, Inc. announced that it has received $1.004004 million in funding	12/22/12	CI
Evolutionary Genomics, Inc. announced that it expects to receive $1.004004 million in funding	24/22/24	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22/22/22	CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt	22/22/22	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	01/21/01	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	07/21/07	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	13/21/13	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	31/21/31	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	14/20/14	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	19/20/19	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	12/20/12	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	30/20/30	CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt	30/20/30	CI
Evolutionary Genomics, Inc. and Eg I, Llc Reports Earnings Results for the Third Quarter Ended September 30, 2019	17/19/17	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	12/19/12	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	15/19/15	CI
Evolutionary Genomics, Inc. announced that it has received $0.49 million in funding	15/19/15	CI
Evolutionary Genomics, Inc. and Eg I, Llc Reports Earnings Results for the Full Year Ended December 31, 2018	02/19/02	CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt	01/19/01	CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2018	15/18/15	CI

Chart Evolutionary Genomics, Inc.

Duration

Period

More charts

Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially traits in crops for the agriculture industry. It uses the Adapted Traits Platform (ATP) to identify commercially valuable genes that control important traits in animals and plants. Its platform identifies genes that have changed successfully to impart new or improved traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The Company uses ATP to perform throughput molecular evolution analysis to identify positively selected genes based on non-synonymous site (Ka) and synonymous site (Ks) analysis.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOLUTIONARY GENOMICS, INC.	-.--%	29.95L
MODERNA, INC.	+40.80%	5.37TCr
LONZA GROUP AG	+35.79%	3.89TCr
IQVIA HOLDINGS INC.	-8.05%	3.88TCr
CELLTRION, INC.	-8.98%	2.73TCr
ICON PUBLIC LIMITED COMPANY	+10.69%	2.59TCr
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	2.03TCr
UNITED THERAPEUTICS CORPORATION	+31.00%	1.28TCr
MEDPACE HOLDINGS, INC.	+28.51%	1.22TCr
BIO-TECHNE CORPORATION	-1.67%	1.2TCr